09:27 AM EDT, 09/29/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Monday that it has resubmitted its biologics license application to the US Food and Drug Administration for Awiqli to treat patients with type 2 diabetes.

The Danish pharmaceutical company said the resubmission of the once-weekly injection of the basal insulin treatment is based on a phase 3a trial of Awiqli.

Shares of Novo Nordisk ( NVO ) were down 3% in recent premarket activity Monday.

Price: 53.90, Change: -1.71, Percent Change: -3.07